Pharma Lab news
Pharma Lab news
Tecan accelerates data-driven lab journey with agentic AI developments powered by NVIDIA
Tecan, a global provider of laboratory automation and solutions, has announced the integration of agentic AI capabilities into its lab analytics platform Introspect, leveraging NVIDIA...
Drug Discovery & Development
Celecor completes submission of FDA new drug application for investigational heart-attack drug
Celecor has submitted the final section of its New Drug Application (NDA) for the company's investigational heart-attack drug, zalunfiban (DisaggproTM), to the US Food...
Clinical Trials Insights
Vascarta announces phase 1 results of VAS-101 administered sublingually in sickle cell disease patients
Vascarta, a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, has announced successful completion of the sublingual arm of its phase 1...
Clinical Trials Insights
Innovative Molecules announces first patient dosed in phase 2a trial of adibelivir, advancing the company into late-stage clinical development
Innovative Molecules, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, has announced the first patient dosed in its phase...
Pharma Lab news
uniQure announces plan for BLA submission for AMT-130 in Huntington’s Disease
uniQure, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, has announced that, during a recent type B meeting...
Pharma Lab news
Eli Lilly to acquire both LimmaTech Biologics and Vaccine company in deals totalling US$2.33billion
Eli Lilly is to acquire LimmaTech Biologics and Vaccine Company. Along with its acquisition of Curevo, the companies will expand Lilly’s research and development...
Drug Discovery & Development
Pentixapharm announces FDA clearance of IND for phase 3 ‘panda’ study of first-in-class cardiovascular diagnostic programme
Pentixapharm, a clinical-stage biotech developing novel radiopharmaceuticals, has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)...
Clinical Trials Insights
Imaavy (nipocalimab-aahu) demonstrates durable haemoglobin response and rapid onset of effect in pivotal phase 2/3 study in warm autoimmune haemolytic anaemia, an autoantibody-driven disease...
Johnson & Johnson is presenting the first comprehensive results from the phase 2/3 ‘energy’ study showing that Imaavy (nipocalimab-aahu) produced a statistically significant durable haemoglobin (Hgb) response with rapid onset...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Latest stories
© 2026 Pharma Press Publishing.